208 related articles for article (PubMed ID: 36937550)
1. A Novel Nanoemulsion Formula for an Improved Delivery of a Thalidomide Analogue to Triple-Negative Breast Cancer; Synthesis, Formulation, Characterization and Molecular Studies.
Tawfik NM; Teiama MS; Iskandar SS; Osman A; Hammad SF
Int J Nanomedicine; 2023; 18():1219-1243. PubMed ID: 36937550
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, Characterization, Molecular Docking, In Vitro Biological Evaluation and In Vitro Cytotoxicity Study of Novel Thiazolidine-4-One Derivatives as Anti-Breast Cancer Agents.
Kadhim ZY; Alqaraghuli HGJ; Abd MT
Anticancer Agents Med Chem; 2021; 21(17):2397-2406. PubMed ID: 33797379
[TBL] [Abstract][Full Text] [Related]
3. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
4. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
Luo Y; Wu W; Zha D; Zhou W; Wang C; Huang J; Chen S; Yu L; Li Y; Huang Q; Zhang J; Zhang C
Bioorg Med Chem Lett; 2021 Sep; 47():128230. PubMed ID: 34186178
[TBL] [Abstract][Full Text] [Related]
8. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
9. [10]-Gingerol-Loaded Nanoemulsion and its Biological Effects on Triple-Negative Breast Cancer Cells.
Zanesco-Fontes I; Silva ACL; da Silva PB; Duarte JL; Di Filippo LD; Chorilli M; Cominetti MR; Martin ACBM
AAPS PharmSciTech; 2021 May; 22(5):157. PubMed ID: 34008089
[TBL] [Abstract][Full Text] [Related]
10. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
11. Half-Lantern Cyclometalated Platinum(II) Complexes as Anticancer Agents: Molecular Docking, Apoptosis, Cell Cycle Analysis, and Cytotoxic Activity Evaluations.
Hajipour F; Mahdavinia M; Fereidoonnezhad M
Anticancer Agents Med Chem; 2022; 22(6):1149-1158. PubMed ID: 34259151
[TBL] [Abstract][Full Text] [Related]
12. Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Asiri A; Soliman KFA
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297339
[TBL] [Abstract][Full Text] [Related]
13. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
14. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
15. DFF40-iRGD, a novel chimeric protein with efficient cytotoxic and apoptotic effects against triple-negative breast cancer cells.
Amrollahi-Nia R; Akbari V; Shafiee F
Biotechnol Lett; 2021 Oct; 43(10):1967-1976. PubMed ID: 34482510
[TBL] [Abstract][Full Text] [Related]
16. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines.
Özgür A; Kara A; Gökşen Tosun N; Tekin Ş; Gökçe İ
Mol Biol Rep; 2021 Apr; 48(4):3439-3449. PubMed ID: 33999319
[TBL] [Abstract][Full Text] [Related]
17. New halogenated constituents from Mangifera zeylanica Hook.f. and their potential anti-cancer effects in breast and ovarian cancer cells.
Ediriweera MK; Tennekoon KH; Adhikari A; Samarakoon SR; Thabrew I; de Silva ED
J Ethnopharmacol; 2016 Aug; 189():165-74. PubMed ID: 27224244
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells.
Alkhatib MH; Bawadud RS; Gashlan HM
Sci Rep; 2020 Oct; 10(1):18124. PubMed ID: 33093596
[TBL] [Abstract][Full Text] [Related]
19. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
20. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
